Genocea biosciences Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Genocea biosciences Contact Number

Contact Genocea

2 hours ago Genocea.com Get All

617.876.8191

Genocea 100 Acorn Park Dr Cambridge, MA 02140 Phone: 617.876.8191 Fax: 617.500.0969

Website: https://www.genocea.com/contact/

Category: Contact SupportShow more

Contact Us — Investor Relations — Genocea Biosciences

3 hours ago Ir.genocea.com Get All

617.876.8191

Genocea 100 Acorn Park Dr Cambridge, MA 02140. Phone: 617.876.8191 Fax: 617.500.0969

Website: https://ir.genocea.com/contact-us

Category: Contact SupportShow more

Genocea Making better cancer immunotherapies for patients.

4 hours ago Genocea.com Get All

Girish joined Genocea in December 2018 as Chief Business Officer. In this role, he leads Genocea’s business development efforts. His broad skill set spans business development, corporate and R&D strategy, product portfolio management, commercial planning, and alliance management – experience he gained at previous positions at the Ipsen Group, a global specialty biopharmaceutical company

Website: https://www.genocea.com/

Category: Contact NumberShow more

Genoceans Genocea

4 hours ago Genocea.com Get All

617.876.8191

Genocea has a high-performing and collaborative culture that embraces equity, diversity, and inclusion as a source of strength. We reject systemic discrimination, exclusion or hatred that promotes a narrow, exclusionary vision for our society. Contact. Genocea 100 Acorn Park Dr Cambridge, MA 02140 Phone: 617.876.8191 Fax: 617.500.0969

Estimated Reading Time: 8 mins

Website: https://www.genocea.com/genoceans/

Category: Contact NumberShow more

Genocea Biosciences Crunchbase Company Profile & Funding

9 hours ago Crunchbase.com Get All

Contact Email [email protected]genocea.com. Phone Number 3094183917. Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as

Founded: 2006
Founders: Kevin Bitterman, Josh Wolfe

Website: https://www.crunchbase.com/organization/genocea-biosciences

Category: Contact NumberShow more

GNCA Genocea Biosciences Inc. • BioPharmCatalyst

5 hours ago Biopharmcatalyst.com Get All

617-430-7576

Investor Contact: Dan Ferry 617-430-7576 About Genocea Biosciences, Inc. CPI-sensitive subjects had a greater number of neoantigens identified with ATLAS at baseline compared with patients in the CPI-refractory cohort, and also had evidence of epitope spread for CD8 + T cells post-dosing.

Website: https://www.biopharmcatalyst.com/company/gnca

Category: Contact NumberShow more

About Genocea

Just Now Genocea.com Get All

Diantha joined Genocea in March 2019, bringing broad life science financial leadership experience to the company. Most recently, Diantha served as Vice President, Controller and Chief Accounting Officer at Bioverativ, Inc. Prior to Bioverativ, she served as U.S. and Global Commercial Controller at Biogen and held a number of positions as an Executive Director at Merck and Co.

Estimated Reading Time: 9 mins

Website: https://www.genocea.com/about/

Category: Contact NumberShow more

SEC FORM D/A

4 hours ago Sec.gov Get All

617-876-8191

GENOCEA BIOSCIENCES, INC. Street Address 1 Street Address 2; 100 ACORN PARK DRIVE, 5TH FLOOR: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02140: 617-876-8191

Website: https://www.sec.gov/Archives/edgar/data/1457612/000157957013000010/xslFormDX01/primary_doc.xml

Category: Contact NumberShow more

SEC FORM D

4 hours ago Sec.gov Get All

617-876-8191

Principal Place of Business and Contact Information. Name of Issuer; GENOCEA BIOSCIENCES, INC. Street Address 1 Street Address 2; 100 ACORN PARK DRIVE: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02140: 617-876-8191: 3. Related Persons. Last Name First Name Middle Name; CLARK: WILLIAM: …

Website: https://www.sec.gov/Archives/edgar/data/1457612/000145761220000130/xslFormDX01/primary_doc.xml

Category: Contact NumberShow more

Pipeline Genocea

3 hours ago Genocea.com Get All

ATLAS™ drives Genocea’s pipeline of potential best-in-class clinical stage cancer immunotherapies, including GEN-011, our neoantigen cell therapy for solid tumors, and GEN-009, our neoantigen vaccine candidate. GEN-009 is a neoantigen vaccine candidate in a Phase 1/2a clinical trial to treat a …

Website: https://www.genocea.com/pipeline/

Category: Contact NumberShow more

Investors — Genocea Biosciences

3 hours ago Ir.genocea.com Get All

Genocea to Present at Upcoming Scientific and Investor Conferences. CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following virtual conferences in September.

Website: https://ir.genocea.com/

Category: Contact NumberShow more

Genocea Biosciences Company Profile Office Locations

6 hours ago Craft.co Get All

Genocea Biosciences has 59 employees at their 1 location and $1.36 M in annual revenue in FY 2020. See insights on Genocea Biosciences including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Website: https://craft.co/genocea-biosciences

Category: Contact NumberShow more

Genocea Provides Fourth Quarter 2020 Corporate Update

1 hours ago Ir.genocea.com Get All

(844) 826-0619

Genocea will host a conference call and webcast today at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 5767897.

Website: https://ir.genocea.com/news-releases/news-release-details/genocea-provides-fourth-quarter-2020-corporate-update

Category: Contact NumberShow more

Company Genocea Biosciences News, Employees and Funding

4 hours ago Topionetworks.com Get All

Genocea Biosciences is harnessing the power of T cells to save and improve millions of lives. Infectious diseases remain an urgent and persistent global health threat, in both the developed and the developing world. Vaccines are recognized as the most cost-effective and successful approach to managing such diseases, yet traditional methods for discovering and developing vaccines are too slow

Website: https://www.topionetworks.com/companies/genocea-biosciences-535f975508f007055300c37e

Category: Contact NumberShow more

Genocea Provides Third Quarter 2020 Genocea Biosciences

Just Now Ir.genocea.com Get All

617-430-7576

These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law. Investor Contact: Dan Ferry 617-430-7576 [email protected] (Tables to follow) GENOCEA BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

Website: https://ir.genocea.com/news-releases/news-release-details/genocea-provides-third-quarter-2020-corporate-update

Category: Contact NumberShow more

Genocea Biosciences Inc Company Profile and News

9 hours ago Bloomberg.com Get All

Company profile page for Genocea Biosciences Inc including stock price, company news, press releases, executives, board members, and contact information

Website: https://www.bloomberg.com/profile/company/GNCA:US

Category: Contact NumberShow more

Genocea Announces Upcoming Data Genocea Biosciences

1 hours ago Ir.genocea.com Get All

Abstract Number: 526 Title: Inhibigen TM-specific responses suppress anti-tumor immunity and promote tumor growth. Per SITC policy, full abstracts are embargoed until 8 a.m. ET on November 9, 2020. About Genocea Biosciences, Inc. Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types.

Website: https://ir.genocea.com/news-releases/news-release-details/genocea-announces-upcoming-data-presentations-virtual-sitc-2020

Category: Contact NumberShow more

Genocea Biosciences, Inc.: Rosen Law

2 hours ago Rosenlegal.com Get All

Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.-----Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34 th Floor New York, NY 10016

Website: https://www.rosenlegal.com/cases-1235.html

Category: Contact NumberShow more

Genocea Biosciences Number of Employees 20122021 GNCA

6 hours ago Macrotrends.net Get All

Genocea Biosciences number of employees from 2012 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Genocea Biosciences, Inc. is involved in developing vaccines.

Website: https://www.macrotrends.net/stocks/charts/GNCA/genocea-biosciences/number-of-employees

Category: Contact NumberShow more

Genocea Biosciences Company Profile: Stock Performance

7 hours ago Pitchbook.com Get All

Description. Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology

Website: https://pitchbook.com/profiles/company/50838-04

Category: Contact NumberShow more

Genocea Provides Second Quarter 2021 Corporate Update

2 hours ago Finance.yahoo.com Get All

Genocea will host a conference call and webcast today at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826 …

Website: https://finance.yahoo.com/news/genocea-provides-second-quarter-2021-110000012.html

Category: Contact NumberShow more

GENOCEA BIOSCIENCES, INC. (Form: 10Q, Received: 04/30

5 hours ago Content.edgar-online.com Get All

Genocea Biosciences, Inc. (the “Company”) is a biopharmaceutical company that was incorporated in Delaware on August 16, 2006 and has a principal place of business in Cambridge, Massachusetts. The Company discovers and develops novel cancer immunotherapies using its ATLAS TM proprietary discovery platform.

Website: https://content.edgar-online.com/ExternalLink/EDGAR/0001457612-19-000062.html?hash=2110fa89aaf5f15de18ca6d86ec513b8deb7553155998bb9cf19813b8385db6b&dest=A1SUBSCRIPTIONAGREEMENTE_HTM

Category: Contact NumberShow more

Is Genocea Biosciences, Inc. (NASDAQ:GNCA) Popular Amongst

3 hours ago Nasdaq.com Get All

Every investor in Genocea Biosciences, Inc. (NASDAQ:GNCA) should be aware of the most powerful shareholder groups. Generally speaking, as a …

Website: https://www.nasdaq.com/articles/is-genocea-biosciences-inc.-nasdaq:gnca-popular-amongst-institutions-2021-09-15

Category: Contact NumberShow more

Genocea to Host Fourth Quarter 2020 Corporate Update

8 hours ago Finance.yahoo.com Get All

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its

Website: https://finance.yahoo.com/news/genocea-host-fourth-quarter-2020-210500639.html

Category: Contact NumberShow more

Genocea to Host Third Quarter 2020 Corporate Update

7 hours ago Finance.yahoo.com Get All

These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.Investor Contact

Website: https://finance.yahoo.com/news/genocea-host-third-quarter-2020-205700730.html

Category: Contact NumberShow more

Genocea Provides First Quarter 2021 Corporate Update

1 hours ago Finance.yahoo.com Get All

GENOCEA BIOSCIENCES, INC.CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)(In thousands) March 31, 2021 December 31, 2020 Cash and cash equivalents $66,035 $79,769 Property and equipment, net

Website: https://finance.yahoo.com/news/genocea-provides-first-quarter-2021-110000567.html

Category: Contact NumberShow more

Genocea Provides First Quarter 2020 Corporate Update

5 hours ago Biospace.com Get All

(844) 826-0619

Genocea will host a conference call and webcast today at 8:30 a.m. EDT. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 4855738.

Website: https://www.biospace.com/article/releases/genocea-provides-first-quarter-2020-corporate-update/

Category: Contact NumberShow more

Genocea Biosciences Total Employees (Annual) GNCA

6 hours ago Ycharts.com Get All

Genocea Biosciences Rallies 11% - Says Data Show Advantages of Its GEN-011 Over TIL Therapy MT Newswires 05/12 17:42 ET Genocea Introduces GEN-011, a Transformational T cell Therapy Designed to Improve on Current Limitations of TIL Therapy

Website: https://ycharts.com/companies/GNCA/total_employee_number

Category: Contact NumberShow more

Genocea to Host Second Quarter 2021 Corporate Update

2 hours ago Globenewswire.com Get All

(844) 826-0619

Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 6789021.

Website: https://www.globenewswire.com/news-release/2021/07/22/2267780/36309/en/Genocea-to-Host-Second-Quarter-2021-Corporate-Update-Conference-Call-Webcast.html

Category: Contact NumberShow more

Genocea to Host Third Quarter 2020 Corporate Update

Just Now Ca.finance.yahoo.com Get All

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quarter 2020 financial results and corporate update conference call and live audio webcast on Thursday, October 29th at 8:30 a.m. EDT.Interested participants may …

Website: https://ca.finance.yahoo.com/news/genocea-host-third-quarter-2020-205700730.html

Category: Contact NumberShow more

Genocea Biosciences Funding, Financials, Valuation

8 hours ago Crunchbase.com Get All

Genocea Biosciences has raised a total of $470.6M in funding over 14 rounds. Their latest funding was raised on Jul 22, 2020 from a Post-IPO Equity round. Genocea Biosciences is registered under the ticker NASDAQ:GNCA . Their stock opened with $13.00 in its Feb 6, 2014 IPO. Genocea Biosciences is funded by 12 investors.

Website: https://www.crunchbase.com/organization/genocea-biosciences/company_financials

Category: Contact NumberShow more

Safety and Immunogenicity Study of Therapeutic HSV2

7 hours ago Clinicaltrials.gov Get All

Genocea Biosciences, Inc. ClinicalTrials.gov Identifier: NCT01667341 Other Study ID Numbers: GEN-003-001 : First Posted: August 17, 2012 Key Record Dates: Last Update Posted: June 1, 2018 Last Verified: May 2018

Website: https://clinicaltrials.gov/ct2/show/NCT01667341

Category: Contact NumberShow more

Genocea Biosciences, Inc. S1 Jun. 7, 2019 4:42 PM

9 hours ago Seekingalpha.com Get All

Unless otherwise indicated below, the address for each beneficial owner listed is c/o Genocea Biosciences, Inc., Cambridge Discovery Park, 100 Acorn Park Drive, Cambridge, MA 02140. Number

Website: https://seekingalpha.com/filing/4525938

Category: Contact NumberShow more

Genocea to Host Fourth Quarter 2020 Corporate Update

1 hours ago Ca.finance.yahoo.com Get All

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth quarter 2020 financial results and corporate update conference call and live audio webcast on Thursday, February 11th at 8:30 a.m. ET. Interested participants may …

Website: https://ca.finance.yahoo.com/news/genocea-host-fourth-quarter-2020-210500639.html

Category: Contact NumberShow more

Current Genocea Biosciences (NASDAQ:GNCA) Technical

9 hours ago Macroaxis.com Get All

As of the 12th of September 2021, Genocea Biosciences retains the risk adjusted performance of (0.08), and Market Risk Adjusted Performance of (0.36).Genocea Biosciences technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Website: https://www.macroaxis.com/technical-analysis/GNCA/Genocea-Biosciences

Category: Technical Support, Tech SupportShow more

GENOCEA BIOSCIENCES, INC. (Form: 8K, Received: 02/12/2019

3 hours ago Content.edgar-online.com Get All

On February 11, 2019, Genocea Biosciences, Inc. (the “Company”) entered into a Subscription Agreement (the “Subscription Agreement”) with certain purchasers identified on the signature pages thereto (the “Purchasers”), pursuant to which the Company will offer to the Purchasers, in an unregistered offering, shares of common stock, par value $0.001 per share (the “Common Stock

Website: https://content.edgar-online.com/ExternalLink/EDGAR/0001457612-19-000022.html?hash=3a19cd150e2de877179c4725ad608d961b1bb03760d949bb6e88a35926566bfe&dest=EX41_PRE-FUNDEDWARRANT_HTM

Category: Contact NumberShow more

Bombs Away: Genocea's Herpes Vaccine Goes Down In Flames

4 hours ago Acsh.org Get All

Bombs Away: Genocea's Herpes Vaccine Goes Down In Flames. By Josh Bloom — September 25, 2017. RIP Genocea's Herpes Simplex Vaccine. For those of you who may have been counting on Genocea's GEN-003 to treat or even cure your genital herpes, this is a very bad day. The company just announced that it was discontinuing the development of 003 as a

Website: https://www.acsh.org/news/2017/09/25/bombs-away-genoceas-herpes-vaccine-goes-down-flames-11874

Category: Contact NumberShow more

Jennifer Herron, of ADC Therapeutics, Joins Genocea

6 hours ago Globenewswire.com Get All

CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced

Website: https://www.globenewswire.com/news-release/2021/09/13/2296189/36309/en/Jennifer-Herron-of-ADC-Therapeutics-Joins-Genocea-Biosciences-Board-of-Directors.html

Category: Contact NumberShow more

Jennifer Herron, of ADC Therapeutics, Joins Genocea

3 hours ago Biospace.com Get All

CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Jennifer Herron, Senior Vice President & Chief Commercial Officer at ADC Therapeutics SA ("ADCT"), has joined its board of directors. “It is my great pleasure to …

Website: https://www.biospace.com/article/releases/jennifer-herron-of-adc-therapeutics-joins-genocea-biosciences-board-of-directors/

Category: Contact NumberShow more

Genocea to Host Second Quarter 2021 Corporate Update

1 hours ago Nz.finance.yahoo.com Get All

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its second quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, July 29th at 8:30 a.m. E.T. Interested participants may access the conference …

Website: https://nz.finance.yahoo.com/news/genocea-host-second-quarter-2021-210500457.html

Category: Contact NumberShow more

Genocea Biosciences, Inc. 10Q Jul. 25, 2019 8:49 AM

9 hours ago Seekingalpha.com Get All

Genocea Biosciences, Inc., et al. , U.S. Court of Appeal for the First Circuit, Case No. 19-1036, was docketed in the First Circuit on January 15, 2019. By order dated January 29, 2019, the First

Website: https://seekingalpha.com/filing/4573475

Category: Contact NumberShow more

Genocea Provides Third Quarter 2020 Corporate Update

5 hours ago Biospace.com Get All

(844) 826-0619

Genocea will host a conference call and webcast today at 8:30 a.m. EDT. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 5951388.

Website: https://www.biospace.com/article/releases/genocea-provides-third-quarter-2020-corporate-update/

Category: Contact NumberShow more

Genocea to Host Second Quarter 2021 Corporate Update

7 hours ago Marketscreener.com Get All

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its second quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, July 29 t h at 8:30 a.m. E.T. Interested participants may access the conference …

Website: https://www.marketscreener.com/quote/stock/GENOCEA-BIOSCIENCES-INC-58808477/news/Genocea-to-Host-Second-Quarter-2021-Corporate-Update-Conference-Call-Webcast-35926736/

Category: Contact NumberShow more

Genocea To Host First Quarter 2021 Corporate Update

Just Now Nz.finance.yahoo.com Get All

CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its first quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, April 29 at 8:30 a.m. ET. Interested participants may access the …

Website: https://nz.finance.yahoo.com/news/genocea-host-first-quarter-2021-203000738.html

Category: Contact NumberShow more

What is Current Genocea Biosciences (NASDAQ:GNCA) Stock

2 hours ago Macroaxis.com Get All

If you would invest 265.00 in Genocea Biosciences on May 4, 2021 and sell it today you would lose (66.00) from holding Genocea Biosciences or give up 24.91% of portfolio value over 90 days. Genocea Biosciences is currently does not generate positive expected returns and assumes 3.5778% risk (volatility on return distribution) over the 90 days horizon.

Website: https://www.macroaxis.com/performance/GNCA/Genocea-Biosciences

Category: Contact NumberShow more

What are Genocea Biosciences (NASDAQ:GNCA) Math Transform

2 hours ago Macroaxis.com Get All

Genocea Biosciences math transform tool provides the execution environment for running the Sine Of Price Series transformation and other technical functions against Genocea Biosciences. Genocea Biosciences value trend is the prevailing direction of the price over some defined period of time.

Website: https://www.macroaxis.com/stocks/Math-Transform/GNCA

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What is the mission of the genocea company?

Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on the tumor.

Who is the chief scientific officer of genocea?

Fun Facts about Diantha: enjoys traveling and skiing especially with her family and is an avid Boston sports fan. Jess joined Genocea in 2007, soon after the company was founded, and currently serves as Chief Scientific Officer.

How does genocea help in the treatment of cancer?

Genocea’s mission is to help conquer cancer through targeted vaccines and immunotherapies. Using our revolutionary ATLAS™ platform to identify true T cell antigens, we are creating new lifelines for cancer patients by listening to and learning from the immune system.

Where did genocea get its immunotherapy from?

He received a B.A. in Biophysics with General and Departmental Honors from Johns Hopkins University, a Ph.D. in Cellular and Molecular Neurobiology following an M.S. in Biology from the California Institute of Technology, and has completed executive education in Corporate Governance at Northwestern University – Kellogg School of Management.

Brand New Updated

Popular Brands

Godrej
Gbl
Geely
Gati
Gic
Gevo
Geron
Gaia
Gpa